Illhwan Cho

Illhwan Cho

Auto-generated profile, based on publicly available information

Illhwan Cho

Yonsei University

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2023 in Marine Drugs
Verified
Journal Article
Open access
PDF file
JCJinsheng Cui
Jinsheng Cui
SYSuhyun Ye
Suhyun Ye
DSDaniel Shin
Daniel Shin
ICIllhwan Cho
Illhwan Cho
HKHye Yun Kim
Hye Yun Kim
DODong-Chan Oh
Dong-Chan Oh
Two new glycosylated and succinylated macrocyclic lactones, succinyl glyco-oxydifficidin (1) and succinyl macrolactin O (2), were isolated from a Bacillus strain collected from an intertidal mudflat on Anmyeon Island in Korea. The planar structures of 1 and 2 were proposed using mass spectrometric analysis and NMR spectroscopic data. The absolute configurations of 1 and 2 were determined by optical rotation, J-based configuration analysis, chemical derivatizations, including the modified Mosher’s method, and quantum-mechanics-based calculation. Biological evaluation of 1 and 2 revealed that succinyl glyco-oxydifficidin (1) inhibited/dissociated amyloid β (Aβ) aggregation, whereas succinyl macrolactin O (2) inhibited Aβ aggregation, indicating their therapeutic potential for disassembling and removing Aβ aggregation.

12 August 2025 in ChemRxiv
Verified
Preprint
Open access
PDF file
SHSeongrok Heo
Seongrok Heo
MCMinhae Cha
Minhae Cha
WZWonho Zhung
Wonho Zhung
SKSirisuk Keereewan
Sirisuk Keereewan
SYSoljee Yoon
Soljee Yoon
SHSunkyu Han
Sunkyu Han
Collinolactone, featuring a 7/10/6 tricyclic core, has been proposed to be biosynthesized via a transannular [6+4] cycloaddition reaction. Besides its intriguing architecture, collinolactone holds pharmaceutical promises due to its ability to disrupt amyloid-β (Aβ) and tau aggregation, which are specifically found as disease culprits in the brains of Alzheimer’s disease (AD) patients and are key targets in current drug discovery efforts. However, challenges associated with its acquisition from a natural source and limited pharmacokinetic properties have hampered its further studies. Herein, we report the design, synthesis, and evaluation of 3-dehydroxy-5-epi-collinoketone, a collinolactone derivative with improved pharmacokinetics for AD treatment. A stereoselective transannular [6+4] cycloaddition efficiently constructed the tricyclic core, allowing its scalable synthesis. AI-assisted simulations predicted superior binding of 3-dehydroxy-5-epi-collinoketone to Aβ and tau aggregates compared to collinolactone. In vitro studies confirmed its inhibition and dissociation of Aβ and tau fibrils, while in vivo experiments in AD mouse models showed substantial amelioration of cognitive functions and Aβ/tau-associated pathology.

1 December 2024 in Alzheimer's & Dementia
Verified
Journal Article
Open access
ICIllhwan Cho
Illhwan Cho
SYSoljee Yoon
Soljee Yoon
HKHye Yun Kim
Hye Yun Kim
YKYoungSoo Kim
YoungSoo Kim
Background: As amyloid‐β (Aβ) aggregates are considered as the biomarkers and key factors in the pathology of Alzheimer’s disease, there has been extensive investigation into Aβ‐targeting compounds for the development of diagnostics and drug discovery related to the disorder. However, the polymorphic and heterogenous nature of Aβ aggregates impedes the structural understanding of their structure. Consequently it is a major challenge to develop new diagnostic and therapeutic development of AD and to study the mechanism of Aβ‐targeting compounds.Method: Utilization of solid‐phase peptide synthesis, 37 Aβ hexameric Aβ fragments were synthesized. These fragments were immobilized on the 96‐well microplane to develop a mapping plate for investigating the active sites of Aβ‐targeting compounds. To confirm the mapping potential of our plate, previously reported fluorescent Aβ‐imaging agents (CRANAD‐28, bis‐ANS), Aβ aggregation inhibitors (curcumin, scyllo‐inositol), and Aβ aggregate dissociators (necrostatin‐1, sunitinib) were treated.Result: Using the mapping plate, we confirmed that CRANAD‐28 interacted with three domains of Aβ HHQKLVFF (Aβ13‐20), IIGLMV (Aβ31‐36), and GGVVIA (Aβ37‐42), and bis‐ANS were bound to the predominant parts of Aβ sequences except N‐terminal regions. We further determined that curcumin inhibited three distinct fragmental regions of Aβ (Aβ14‐21, Aβ29‐35, and Aβ37‐42) and scyllo‐inositol targeted VHHQKLVFF (Aβ12‐20), VGSNKGAIIGL (Aβ24‐39), and GGVVIA (Aβ37‐42) sites. Lastly, we confirmed that both necrostatin‐1 and sunitinib strongly dissociated GLMVGGVVIA (Aβ33‐42), the C‐terminal hydrophobic residue.Conclusion: This mapping plate can be employed to understand the active sites of Aβ‐targeting compounds, even in the lack of a comprehensive structural understanding of Aβ aggregates. Moreover, the insights gained from identifying targeting sites using this mapping plate can contribute to the rational approach in the development of diagnostic and therapeutic strategies for Alzheimer’s disease (AD).

1 December 2024 in Alzheimer's & Dementia
Verified
Journal Article
Open access
ICIllhwan Cho
Illhwan Cho
MCMinhae Cha
Minhae Cha
HKHye Yun Kim
Hye Yun Kim
YKYoungSoo Kim
YoungSoo Kim
Background: Cyclin Y (CCNY) is a member of cyclin protein family inhibiting long‐term synaptic plasticity, which is related to the learning and memory function in neuronal system. Recently, CCNY has been reported to associate with the cognitive deficits in Alzheimer’s disease (AD).Method: In this study, we discovered PFTAIRE peptide to diminish CCNY protein level and to ameliorate cognitive dysfunction in AD. This peptide is derived from the domain of cyclin‐dependent kinase 14, a kinase degrading CCNY protein, and this domain is essential for the binding to CCNY. Utilizing solid‐phase peptide synthesis, PFTAIRE peptide was produced.Result: We observed that PFTAIRE peptide binds to CCNY protein in in vitro studies. We confirmed the plasma and liver microsomal stability of the peptide and the ability to penetrate blood brain barrier. We intravenously injected PFTAIRE peptide to AD mouse models and performed behavior tests. PFTAIRE peptide prevents memory impairments in AD mouse models. In the proteomic analysis of the cortical brain section of mouse models, we observed the alteration of 93 proteins by the PFTAIRE peptide compared to non‐treated groups. Utilizing gene ontology, PFTAIRE peptide up‐regulated proteins related to release/transport neurotransmitter in brain synapse and down‐regulated proteins related to oxidative stress.Conclusion: Overall, the discovery of PFTAIRE peptide suggests new approach for the development of therapeutics targeting AD.